Category Archives: Dermatology

Dermatology

Galderma announces expansion plans to better serve healthcare professionals and institutions in Malaysia – Yahoo Finance

KUALA LUMPUR, Malaysia, March 30, 2023 /PRNewswire/ -- Galderma, the pure-play dermatology company, announces a change in its marketing operations to better serve the healthcare community in Malaysia. Through this development, the company has established its own team of marketing personnel, product specialists and brand representatives to engage with healthcare professionals and institutions directly. The transfer of commercial activities (sales and marketing) of the company from Zuellig Pharma Sdn Bhd has taken effect since January 2023.

Galderma

"Our goal is to continue supporting our strong growth trajectory with an enhanced focus that will significantly increase our ability to engage and better serve our healthcare community. This year, Galderma will be focusing on broadening engagement sessions with healthcare professionals that are thought leadership in nature and is backed with dermatology science. This expansion plan is in line with the company's business strategy to consistently expand its synergistic portfolio of flagship brands, supported by science-based product differentiation and premium positioning to match consumer and patient needs with superior outcomes. At Galderma, we understand that our skin shapes our lives. We are advancing dermatology for every skin story."CINDY TIUCOUNTRY MANAGER, GALDERMA MALAYSIA

Galderma Malaysia provides a comprehensive product portfolio including Cetaphil(Malaysia's #1 dermatological skincare brand), Epiduo, Differin, Restylane, Sculptra, Tri-Luma, Benzac, Retacnyl, Rozex, Loceryl, Clobex. The announcement of this expansion comes as part of Galderma's next phase of growth for Malaysia.

In 2022, Galderma delivered strong performance globally with 13.9% year-on-year net sales growth on a constant currency basis, driven by innovation and commercial performance. The sustained growth momentum was fueled by continued strong performance in Injectable Aesthetics and Dermatological Skincare[1].

Story continues

Galderma delivers an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market. Galderma's unique portfolio of anti-acne products is the number one choice worldwide[2]. Additionally, Galderma is known for its diverse portfolio of injectable technologies with over two decades of aesthetic innovation and experience from over 85 million treatments worldwide. Cutting-edge innovation is also at the core of Galderma's Dermatological Skincare product category, with clinical data showing that Cetaphil's formula defends against 5 signs of skin sensitivity (dryness, roughness, irritation, tightness and weakened skin barrier) and helps restore and rebuild the skin moisture barrier.

For more information: http://www.galderma.com

Cision

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/galderma-announces-expansion-plans-to-better-serve-healthcare-professionals-and-institutions-in-malaysia-301785872.html

SOURCE CETAPHIL

Read this article:

Galderma announces expansion plans to better serve healthcare professionals and institutions in Malaysia - Yahoo Finance

Dermatology

Introducing Cortina, the only all-inclusive tele-dermatology platform … – The Knockturnal

Do you know Dr. Shah? Who also goes by @DermDoctor on TikTok. Shah was recently announced as the Medical Content Advisor of Cortina and believes in the promise of personalized medicine that it offers.

With Cortina, users get access to a U.S. Board-Certified dermatologist for their skin diagnosis and a personalized treatment plan based on their specific skin condition delivered directly to them. As reiterated by Dr. Shah and Dr. Maclellan (Founder & CEO of Cortina), Cortina solves a major problem when it comes to dermatology, and thats access. Theres a huge supply and demand problem when getting in front of a skin specialist. Cortina solves that.

You may have heard of this approach to skincare in the past, so what sets Cortina apart?

Unlike others, Cortina dermatologists share diagnoses within 24 hours and offer you 24/7 access to your doctor.

Cortina recognizes that there is no one-size-fits-all approach to skincare, so they work to address the most common skin conditions convenient and accessible in all 50 states in the country.

Thus, creating the perfect marriage between modern medicine and modern convenience.

The platform is super affordable priced at a monthly subscription cost of $29.99/month

Naturally, the next concern is likely to be the question of insurance and if yours covers Cortina.

No insurance is required. Theres no catch.

So, what is 2828?

The 2828 line is over-the-counter and supplementary to prescription products recommended by doctors on the Cortina platform.

What skin problems does Cortina treat?ACNE | HYPERPIGMENTATION | ROSACEA | HAIR LOSS (MEN/WOMEN)

The team is committed to changing healthcare for the better and seeks to build confidence and improve the quality of life of their patients so they can wear their armor proudly.

Read the original here:

Introducing Cortina, the only all-inclusive tele-dermatology platform ... - The Knockturnal

Dermatology

Multidimensional evaluation of offline and online education in … – BMC Medical Education

The novel COVID-19 outbreak has led to the emergence of online teaching in many universities around the world for more than two years [8]. The online teaching system is constantly supplemented and improved, and more and more research on online teaching is conducted to provide more suggestions on online teaching [9, 10]. Our research provides more data and theoretical basis for online teaching in the field of dermatology teaching.

As young college teachers, we have a lot of confusions in the process of online dermatology teaching. Most internships and clinical skills practice have been transferred to online teaching, so students cannot accurately experience the learning of skin lesions and the patients perception. Meanwhile, the medical history collection can only be completed between students, and they cannot deeply understand the feelings of patients themselves and various emergencies in the process of medical history collection, which results in the limitations of online learning of clinical practice ability [11, 12]. Our research results also reflect this teaching problem. Many students can learn from textbooks on their own, do well in the theoretical study of dermatology, and get satisfactory results in the final examination, but the clinical practice of identifying skin lesions cannot be the same as the theoretical learning process. We selected some confused outpatient clinical pictures for students to judge and write the main points of skin disease inquiry, and the scores were not good. The reason is that the profound understanding of morphology cannot be completely learned from the books [13]. It is necessary to have face-to-face communication with patients through outpatient and ward internship and practice, and students can well define skin diseases combined with comprehensive actual touching of skin lesions, some dermatological physical examination (such as detection of Nikolsky sign, dermographism and Auspitz sign), actual feelings of patients and other clinical data [14,15,16].

Furthermore, from the learning feedback and questionnaire survey of students, it also reflected the problems of clinical skills test. The students in the online teaching group reported less interaction with their classmates and teachers, some limitations in palpation and understanding of skin lesions, and some limitations in their overall knowledge of skin diseases. These findings are in line with our expectations and are consistent with other studies on online teaching [17, 18], which has pointed out many similar limitations of online teaching in other disciplines. It is easy to understand that there are space limitations in online teaching, and students focus will be scattered, and they will not be able to communicate with patients. This poses a challenge to the teaching of morphology. We are also thinking about whether we can develop better online teaching software or system through artificial intelligence technology. Through haptic simulation system and Virtual Reality system [19, 20], students can feel the touching feeling of skin lesions online or conduct physical examination of skin diseases, so that students can better experience skin lesions in their own position. It may be better to improve the effect of online teaching in dermatology.

Firstly, this study was only conducted in our hospital, and perhaps the online teaching system in our hospital is not perfect enough, which may also lead to insufficient teaching effect. Therefore, a multi-center study with a larger sample size is needed to comprehensively evaluate the shortcomings of online teaching in dermatology. Secondly, our survey was conducted through an online questionnaire, and the validity of the questionnaire has not been verified, and recall bias and misclassification may exist. Thirdly, we think that there is a lack of more evaluation methods in the examination of clinical skills. If necessary, we can add the actual operation such as fungal microscopic examination and Nikolsky sign examination to evaluate.

Read the original here:

Multidimensional evaluation of offline and online education in ... - BMC Medical Education

Dermatology

Taking Care of Your Skin Now Will Pay Off in the Future – Palm Springs Life

Taking good care of your skin pays dividends when it comes to your appearance. Yet theres far more to being proactive than meets the eye. As skin is the bodys largest organ, taking care of it is also vital to maintaining your overall health.

In our sunny climate, the risk of developing skin cancer is compounded. First rule of thumb is to have a yearly skin check performed by an experienced dermatologist. That red, scaly bump youve been ignoring just might be a precancerous lesion. Chances are its a basal or squamous cell skin cancer the two most common types but anything new, changing, or unusual on both sun-exposed and sun-protected areas of the body is worth investigating. It could be melanoma.

Fortunately, the days when melanoma was the equivalent of a death sentence are behind us. Dr. Timothy Jochen of Contour Dermatology, with offices in Palm Springs, Rancho Mirage and La Quinta, points to the progress being made with a game-changing form of cancer tissue testing.

Were starting to do gene expression profile testing where we can identify people who are most at risk for recurrence of melanoma as well as those who are at more risk for metastases. Jochen also underlines the advances being made with anti-program death receptor inhibitors, an injectable form of immunotherapy.

Melanoma, like most cancers, is skilled at hiding from the bodys immune system. What anti-program death receptor inhibitors have been able to do is turn the immune system back on, so your body will actually go and fight the melanoma where it went incognito before, says Jochen, emphasizing that these are very exciting times for dermatology.

Meanwhile, basal and squamous cell varieties of skin cancer are eminently treatable. Methods run the gamut from medicated creams to Mohs surgery, which offers the highest cure rate for difficult-to-treat and/or invasive cases. More recently, Contour Dermatology and other dermatology practices are finding great success employing multiple low-radiation treatments as an alternative to surgery.

New and improved treatment methods have emerged to treat other common skin conditions that vex people as well. For instance, inflammatory skin disorders such as eczema and psoriasis are benefiting from immune modulator treatments. When topical therapies fail, we can move on to these oral or injectable medications that can actually control these disorders if you have a severe disease process, Jochen explains.

Excerpt from:

Taking Care of Your Skin Now Will Pay Off in the Future - Palm Springs Life

Dermatology

Oral Roflumilast Effective in the Treatment of Plaque Psoriasis – Medpage Today

Oral roflumilast (Daliresp) may be an inexpensive and effective treatment option for patients with psoriasis who are candidates for systemic therapy, according to research presented at the American Academy of Dermatology (AAD) annual meeting.

MedPage Today brought together three expert leaders in the field: moderator Melinda Gooderham, MSc, MD, a dermatologist and clinical researcher from Peterborough, Ontario, is joined by Jennifer Soung, MD, a dermatologist and director of clinical research at Southern California Dermatology in Orange County, and Geeta Yadav, MD, founder of FACET Dermatology in Toronto, for a virtual roundtable discussion. This last of four exclusive episodes focuses on the results of a phase II randomized trial evaluating the efficacy and safety of oral roflumilast in adults with moderate-to-severe plaque psoriasis.

Following is a transcript of their remarks:

Gooderham: Hello, I'm Melinda Gooderham. I'm a dermatologist and clinical researcher from Peterborough, Ontario, at the SKiN Centre for Dermatology and an assistant professor at Queen's University. I wanted to welcome you to this roundtable discussion on top news from AAD 2023, and I'm delighted to have with me today, Dr. Geeta Yadav, who is the founder and medical director at FACET Dermatology in Toronto and a lecturer at the University of Toronto, and Dr. Jennifer Soung, who is the director of clinical research at Southern California Dermatology and is on the clinical faculty at Harbor-UCLA.

All right, so moving on that same theme of PDE4 inhibition, there was another investigator-initiated poster presented at the late-breakers. The efficacy and safety of oral roflumilast in the treatment of moderate-to-severe psoriasis, a randomized, double-blinded, placebo-controlled trial, which they named PSORRO.

This was done in Denmark without any industry funding. So that was an interesting one for the late breakers, it's good for them. So they looked at roflumilast 500 mcg once a day versus placebo for the first 12 weeks. They had 23 patients randomized to each arm. At week 12, the placebo patients rolled over to receive open-label oral roflumilast, the same dose 500 mcg once a day.

So total 24 week study and eligibility criteria were quite similar to any other psoriasis clinical trial with adults. And PASI [Psoriasis Area and Severity Index], BSA [body surface area] similar to the other phase III programs. And they had some baseline characteristics, again that were quite typical -- average age late 30s, two-thirds to three-quarters that were male there in Denmark. So they had 100% Caucasian patients. Their baseline characteristics, the median PASI was about 10, BSA 10 to 14%, sPGA [static Physician's Global Assessment] of 2, with a significant impact on DLQI [Dermatology Life Quality Index] about 9 to 10.

So what they found at the 12-week mark and the primary endpoint being PASI 75 at week 12 was 35% of roflumilast patients achieving the PASI 75 compared to 0%. So there was like no placebo response in that first 12 weeks. Placebo patients then switched over and in 12 weeks they had a 39% PASI 75 rate. So fairly consistent results, and also consistent to what we have seen with other PDE4 inhibitors, such as apremilast [Otezla], in that sort of 30 to 40% range of PASI 75, although it was week 16 with apremilast.

So we saw a nice mean change from baseline and PASI in the drug group. The placebo group had no reduction until they were rolled over onto the drug. And you could see the drug worked well across groups, and even in PASI 90, one-fifth of patients were able to achieve a PASI 90 in this study.

So for tolerability, we know PDE4, as we just discussed, gastrointestinal intolerance seems to be one of the main issues. And here we did see some high rates of diarrhea.

Dr. Yadav, you were mentioning before about the importance of safety and tolerability. What do you think about this AE [adverse event] chart?

Yadav: Yeah, it does make me mindful that it's not just the safety story, it's also the tolerability story. And I think, again, we take some of these things a little bit for granted with the agents that we've had available to our patients in the last decade-plus. And so as we move into adding more therapeutics into our toolbox, I think safety is definitely where the focus is going to be in the next coming years. But also tolerability as we try to kind of broaden the target and find the balance because there's no point in having a drug that's very safe but totally intolerable.

And weirdly when we look at the numbers here, the placebo group had very high rates of diarrhea, like 30%. So it is comparable to the treatment arm. However, it's not sort of, to me, consistent with what I'd expect in like baseline population numbers. And maybe that's just because the number of people in this study was quite small, so maybe it's not reflective.

Gooderham: Yeah, it's interesting because there was 0% efficacy in the placebo, but they had the same AEs. Dr. Soung, what did you think about this poster, or presentation?

Soung: You know, I was really curious because we certainly have many treatments for psoriasis that are highly effective but are expensive. So what makes oral roflumilast here unique is that, one, it's already internationally approved for use in severe COPD [chronic obstructive pulmonary disease]. So we have a history of safety that's established not in our population, but a history of safety. And there are generic versions available in the U.S. So it can be a very inexpensive option, especially for our patients who are non-insured or who are on Medicare and can't afford other treatment options.

So, I'm really curious and happy to see that someone here is exploring oral roflumilast in our psoriasis patients.

Gooderham: Yeah, no, I think that was great. I believe Professor [Alexander] Egeberg said it's cheaper than a Starbucks a day. So I think in Denmark they have the same issues with accessibility and so it is nice to have a medication that can be more affordable for some patients, like, as you say, who are maybe uninsured and don't have access to some other treatment. So that's great.

Tolerability always an issue. We've been dealing with it for years with apremilast. So, many patients take it with no problem, they have no tolerability issues. So I think it's great and hats off to them for going and doing that investigator-initiated study. That's really great.

So I wanted to thank both of you so much again in your crazy busy schedules at the AAD this year to take some time and talk about these late-breaker sessions. I think it's really an exciting time right now, for awhile now in dermatology, with new mechanisms of action, oral therapies, in addition to our biologic therapies. So thanks very much to both of you for taking the time to talk about these today.

Soung: Always a pleasure.

Yadav: Likewise. Thank you.

Watch episode one here: Trial of Novel TYK2 Inhibitor Hits Its Endpoint in Plaque Psoriasis

Watch episode two here: Switch to IL-23 Blocker Yields Deep Responses in Recalcitrant Plaque Psoriasis

Watch episode three here: Orismilast Clears Skin in Moderate-to-Severe Psoriasis

Greg Laub is the Senior Director of Video and currently leads the video and podcast production teams. Follow

See original here:

Oral Roflumilast Effective in the Treatment of Plaque Psoriasis - Medpage Today

Dermatology

Aclaris Therapeutics Emerges as a Promising Player in Medical and … – Best Stocks

Aclaris Therapeutics, Inc. has been making waves in the medical and aesthetic dermatology and immunology industry with its novel drugs. The biopharmaceutical company has earned a consensus rating of Moderate Buy from eight brokerages that are presently covering the stock, according to Bloomberg reports. One investment analyst has rated the stock with a sell rating, while seven have issued a buy rating on the company. This highlights that the industry sees potential in Aclaris Therapeutics innovation.

The average one-year price objective among analysts who have covered the stock in the last year is $32.00 this suggests that investors believe theres scope for growth in this space.

Moreover, several hedge funds have recently bought and sold shares of ACRS, adding to positive investor sentiment towards the biotechnology company. For instance, JPMorgan Chase & Co raised its holdings in Aclaris Therapeutics by 20% in Q1 2021, MetLife Investment Management LLC increased its position by 58.5%, Rhumbline Advisers increased its position by 18.1%, Allianz Asset Management GmbH increased its position by 44.2%, and Vanguard Group Inc increased its position by 0.4%. As a result, approximately 95% of the stock is currently owned by institutional investors and hedge funds.

In conclusion, Aclaris Therapeutics is proving to be a game-changer in medical and aesthetic dermatology and immunology treatments with its innovative products earning approval from industry players. The firm certainly looks poised for growth with an expanding investor base looking to capitalize on this success story. As such, it remains well-positioned to sustain its momentum into breakthrough innovations in drug development at both therapeutic and contract research levels for years to come!

Aclaris Therapeutics: A Leader in Biopharmaceutical Research

Aclaris Therapeutics is a biopharmaceutical company that operates with the objective of identifying, developing, and commercializing novel drugs to address medical and aesthetic dermatology and immunology requirements. The firms primary goal is to deliver cutting-edge treatments that cater to unfulfilled needs in medical fields.

HC Wainwright has conducted extensive studies on Aclaris Therapeutics, reducing its target price from $50.00 to $43.00 while maintaining a buy rating on the stock in a research report on March 7th of this year. Similarly, Stifel Nicolaus initiated coverage on shares of Aclaris Therapeutics, setting a buy rating and a $29.00 target price on the stock in December 2016.

Cantor Fitzgerald reiterated an overweight rating and set a $38.00 target price while The Goldman Sachs Group reduced their target price from $25.00 to $21.00 but retained their buy rating on March 7th.

However, StockNews.com initiated coverage on shares of Aclaris Therapeutics in March 2017 by setting a sell rating on the stock.

Despite mixed reviews from equities research analysts, CEO Douglas J. Manion stands strong in his belief about his companys potential for success as he acquired 6,500 shares of the companys business stock at an average cost of $7.74 per share in early March.

On another note, Director Neal Walker sold 25,000 shares of the companys stock for an average cost of $15.25 per share in January this year, valued at approximately $381K.

Shares of Aclaris Therapeutics opened at $8.25 on Thursday with a market capitalization value of over half-a-billion dollars ($550M), P/E ratio -6.20, and beta 0.60. Aclaris Therapeutics has a 1-year low of $5.77 and 1-year high of $18.96, with a 50-day moving average price of $12.02 and a two-hundred day moving average price of $14.56.

Aclaris Therapeutics released its quarterly earnings data on February 23rd, with the biotechnology company revealing earnings per share of ($0.41) for that quarter, which surpassed the consensus estimate of ($0.44) by $0.03.

Analysts predict that Aclaris Therapeutics will post -1.73 EPS for this year, reflecting positive results from recent studies conducted in the previous quarters.

In conclusion, the market conditions and mixed analyst ratings do not undermine Aclaris Therapeutics massive potential as one of the leading biopharmaceutical innovators in todays medical industry.

More here:

Aclaris Therapeutics Emerges as a Promising Player in Medical and ... - Best Stocks

Dermatology

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin – Dermatology Times

Adolescent patients with acne-prone skin experienced improvements to their skins appearance and overall quality of life after using a dermocosmetic product containing silybum marianum fruit extract (SMFE), according to a recent study.1

The study, published in the Journal of Cosmetic Dermatology, sought to evaluate factors such as safety, tolerability, and efficacy of Avenes Cleanance Comedomed, a product containing SMFE, in adolescents and young adults with acne-prone skin.

Dermocosmetic products are often used to maintain or enhance the tolerance and effectiveness of medical anti-acne therapies, study authors wrote. Recent discoveries about the pathophysiology of acne-prone skin indicate that skincare products may help maintain homeostasis around the sebaceous gland progenitor cells, thereby preventing microcomedone formation.

The observational study, conducted internationally across several study centers, involved 4230 patients ranging from 12 to 25 years of age. All participants were required to meet the established age criteria and have mild-to-moderate acne. This was determined by the global evaluation of acne (GEA) scale.

Prospective participants were excluded from participation in instances of product ingredient sensitivity, were pregnant or breastfeeding, had been diagnosed with a medical condition that may have interfered with signs of acne, or if they had previously participated in another clinical study 1 month prior to the studys start.

From the overall patient population, participants fell into 1 of 3 subcategories: initial therapy (n=1981), associated therapy (n=2044), and maintenance therapy (n=205).

Initial therapy participants had been prescribed the product as a stand-alone treatment, excluding other acne therapies. Associated therapy participants were prescribed the product in addition to topical or systemic acne treatments, and maintenance therapy participants were prescribed the study product after completing other acne treatments.

Participants were involved in 2 visits: 1 at the beginning of the study and 1 follow-up visit after 8 to 12 weeks. At the inclusion visit, researchers collected demographic data, clinical data, and skin care or product routine data. Additionally, participants individually completed questionnaires to evaluate overall quality of life.

Results were analyzed using global tolerance and global effectiveness evaluations. Dermatologists participating in the study based these evaluations on baseline and follow-up GEA scoring. They also analyzed changes in participants quality of life and evaluated the products cosmetic properties.

At the final follow-up visit, researchers assessed clinical results, adverse effects, or reactions, and participants again completed a questionnaire.

By the conclusion of the study, dermatologists had determined that 95% of participants had a good to very good global tolerance of the study product. Dermatologists also reported that the study product was effective or very effective in 80% of participants.

Participants also had an absolute relative GEA score reduction of 0.8 by the studys conclusion. The average decrease in participants Cardiff acne disability index score (assessing quality of life) was significant from the studys start to finish.

In total, researchers reported 165 adverse effects, though it is not reported how many of these were mild, moderate, or severe in nature, nor was it indicated within the study what these adverse effects included.

With these assessments in mind, study authors said the product was effective in 3571 out of 4230 participants.

Researchers said potential study limitations included the absence of a placebo and a lack of compliance monitoring.

This product containing SMFE is the first topical product identified as being able to modulate the comedone-switch mechanism, study authors wrote. "This real-life, international, multicenter study indicated that a skincare product containing SMFE was very well tolerated and might be highly effective for the management of acne-prone skin in adolescent and young adult patients. This dermocosmetic product could therefore be used initially or after an anti-acne therapy to help maintain healthier skin and acne remission in patients with acne-prone skin, who may then be able to limit their use of drug therapies.

Reference

Go here to see the original:

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin - Dermatology Times

Dermatology

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases – Yahoo Finance

Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases

Dermatology industry veteran Thibaud Portal, PhD appointed as CEO

LONDON, March 30, 2023 /PRNewswire/ --Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies., Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development.

Since starting work on these concepts in 2019 with backing from Medicxi, Granular has gained a deep understanding of the biology of mast cells and their role in chronic inflammatory diseases. It has developed a pipeline of next-generation approaches that selectively target mast cells. This approach can drive direct and specific mast cell inhibition, avoid systemic toxicity and enable safe chronic dosing for mast cell driven diseases such as chronic urticaria or systemic mastocytosis.

Brian Kim, Scientific Advisory Board member of Granular Therapeutics, remarked: "Recent data in the field of mast cell driven diseases like Urticaria have shown that tremendous efficacycan be attained, but safety concerns still remain, especially in chronic disease settings. Granular offers a next generation modalitythat offers the promise of increased selectivity and safety."

As Granular embarks on the development of its mast cell targeting pipeline of therapies towards clinical phases, it has appointed a dermatology expert, Dr Thibaud Portal, as Chief Executive Officer. Thibaud Portal is a dermatology specialist who was previously Head of Prescription Medicines business and strategy at Galderma SA andis also co-founder of multiple dermatology focused start-up companies. Dr Jonny Finlay, who co-founded Granular and oversaw the discovery phases, will continue to advise the company and will serve on its Board of Directors.

Story continues

Thibaud Portal, Chief Executive Officer of Granular Therapeutics, commented: "I am honored and delighted to join the Granularteam. Selective mast cell targeting offers outstanding opportunities to address a range of disease indications with a high unmet medical need. I believe this new approach is a significant advancement in the field of chronic inflammatory diseases and that Granular has most exciting pipeline in the field."

Jonny Finlay, Co-founder and Member of the Board of Directors of Granular Therapeutics said:"Finalising the selection of our first clinical candidate is a critical milestone for our company. It is the ideal time to add new competences to the company in order to optimise the positioning of Granular's innovative portfolio of exciting assets across high priority therapeutic areas in the field of chronic inflammatory diseases."

Francesco De Rubertis, Chairman of Granular Therapeutics, added: "We are pleased to welcome Thibaud to Granular's leadership team at this pivotal time of Company growth. As we approach important inflection points, Thibaud's expertise and knowledge will be invaluable in making defining decisions for the future of our innovative programmes."

About Granular Therapeutics

Granular Therapeutics is a UK-based biotechnology company backed by Medicxi, focusing on treatment of mast cell driven diseases. The company was co-founded by Jonny Finlay and Jamie Coleman. Jonny is an industry veteran withtwo decades of experience in biologics discovery and development in academia, government and pharma whosecareer spanned CBER-FDA, Wyeth and Pfizer before becoming a Biotech entrepreneur and the founder of Biotech UltraHuman which spun out of LockBody Therapeutics (now a Centessa company), and Granular Therapeutics. Jamie has been involved for many years in the interface between software, healthcare and investment and co-founded UK-based tech incubator CodeBase, as well as UltraHuman. Granular's CSO, Orla Cunningham was previously Senior Director of Pfizer's BioMedicine Design Group leading multi-disciplinary teams across diverse research units andsupported discovery programmes from conception through to late-stage development. For further information, please visit http://www.granulartherapeutics.com

About Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.For more information, please visit: https://www.medicxi.com.

Cision

View original content:https://www.prnewswire.com/news-releases/granular-therapeutics-to-accelerate-development-of-next-generation-pipeline-for-treating-mast-cell-driven-diseases-301785554.html

SOURCE Granula Therapeutics

Read more:

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases - Yahoo Finance